ProMIS Neurosciences said a new peer-reviewed paper published in Alzheimer’s & Dementia: Translational Research & Clinical Interventions underscores the importance of selectively targeting toxic amyloid-beta (Aβ) oligomers—rather than monomers or plaque—in Alzheimer’s disease therapy. The company claims this selective focus may improve clinical outcomes and reduce the risk of amyloid-related imaging abnormalities (ARIA), a known side effect associated with many existing Aβ-directed antibody treatments.
The publication, titled “Relationship between efficacy and preferential targeting of soluble Aβ aggregates,” compares the binding profiles of multiple Aβ-targeted antibodies to different forms of Aβ species. According to the study, clinical efficacy in Alzheimer’s disease correlates strongly with an antibody’s ability to bind toxic soluble oligomers even in the presence of abundant non-pathogenic monomers, which can otherwise divert therapeutic activity. PMN310—ProMIS’s lead antibody candidate—demonstrated the highest resistance to competition from monomers, preserving its ability to bind oligomers in vitro.
In preclinical models, this oligomer selectivity translated into full protection of spatial memory performance, restoring function to levels seen in normal wild-type mice. The data further showed that PMN310 does not bind to insoluble plaque or vascular amyloid deposits across tested concentrations, a feature that’s believed to reduce the risk of ARIA compared with other Aβ antibodies that do bind plaque. In chronic high-dose mouse studies, no microhemorrhages—a hallmark of ARIA—were observed.
The paper positions PMN310 as uniquely able to test the “oligomer-only” targeting hypothesis in clinical settings without confounding cross-reactivity with monomers or plaque. ProMIS is advancing a Phase 1b clinical trial known as PRECISE-AD, designed to evaluate safety, tolerability and biomarkers in patients with early Alzheimer’s disease. A blinded six-month interim analysis is expected in the second quarter of 2026, with top-line results anticipated in the fourth quarter of 2026.
Overall, the publication reinforces ProMIS’s strategy of focusing on the most pathogenic forms of Aβ, suggesting that precision targeting of toxic oligomers could offer both improved therapeutic efficacy and a more favourable safety profile relative to therapies that also engage plaque and monomer Aβ species.
